{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T03:55:01Z","timestamp":1778817301251,"version":"3.51.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"DOI":"10.1038\/s41698-025-01189-w","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T11:37:21Z","timestamp":1764329841000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["HER2 expression in cervical squamous cell carcinoma: high prevalence of HER2-low\/ultralow and spatiotemporal heterogeneity across tumor evolution"],"prefix":"10.1038","volume":"9","author":[{"given":"Wei","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanmei","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keyi","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiqing","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Lei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuqin","family":"Weng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wucheng","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingcheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Libin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenxiu","family":"Miao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juncheng","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tongmei","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"1189_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"1189_CR2","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1146\/annurev-biochem-060614-034402","volume":"84","author":"E Kovacs","year":"2015","unstructured":"Kovacs, E. et al. A structural perspective on the regulation of the epidermal growth factor receptor. Annu. Rev. Biochem. 84, 739\u2013764 (2015).","journal-title":"Annu. Rev. Biochem."},{"key":"1189_CR3","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/nrc3309","volume":"12","author":"Y Yarden","year":"2012","unstructured":"Yarden, Y. & Pines, G. The ERBB network: at last, cancer therapy meets systems biology. Nat. Rev. Cancer 12, 553\u2013563 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"1189_CR4","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1111\/his.13704","volume":"73","author":"T Koopman","year":"2018","unstructured":"Koopman, T. et al. HER2 immunohistochemistry in endometrial and ovarian clear cell carcinoma: discordance between antibodies and with in-situ hybridisation. Histopathology 73, 852\u2013863 (2018).","journal-title":"Histopathology"},{"key":"1189_CR5","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1158\/1078-0432.CCR-18-2275","volume":"25","author":"F Meric-Bernstam","year":"2019","unstructured":"Meric-Bernstam, F. et al. Advances in HER2-targeted therapy: novel agents and opportunities beyond breast and gastric cancer. Clin. Cancer Res. 25, 2033\u20132041 (2019).","journal-title":"Clin. Cancer Res."},{"key":"1189_CR6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ygyno.2020.07.016","volume":"159","author":"BK Erickson","year":"2020","unstructured":"Erickson, B. K. et al. Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: a multi-institutional cohort study. Gynecol. Oncol. 159, 17\u201322 (2020).","journal-title":"Gynecol. Oncol."},{"key":"1189_CR7","doi-asserted-by":"publisher","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","volume":"22","author":"Y Ogitani","year":"2016","unstructured":"Ogitani, Y. et al. DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin. Cancer Res. 22, 5097\u20135108 (2016).","journal-title":"Clin. Cancer Res."},{"key":"1189_CR8","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/j.drudis.2020.12.014","volume":"26","author":"RK Dhritlahre","year":"2021","unstructured":"Dhritlahre, R. K. & Saneja, A. Recent advances in HER2-targeted delivery for cancer therapy. Drug Discov. Today 26, 1319\u20131329 (2021).","journal-title":"Drug Discov. Today"},{"key":"1189_CR9","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","volume":"391","author":"A Bardia","year":"2024","unstructured":"Bardia, A. et al. Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer. N. Engl J. Med. 391, 2110\u20132122 (2024).","journal-title":"N. Engl J. Med."},{"key":"1189_CR10","doi-asserted-by":"publisher","first-page":"5528","DOI":"10.1200\/JCO.2024.42.16_suppl.5528","volume":"42","author":"G Yuan","year":"2024","unstructured":"Yuan, G. et al. Evaluation of the effectiveness and safety of disitamab vedotin in HER2-expressing 2L recurrent or metastatic cervical cancer (r\/mCC): interim results of RC48-C018. J. Clin. Oncol. 42, 5528 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1189_CR11","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.1200\/JCO.22.02864","volume":"41","author":"AC Wolff","year":"2023","unstructured":"Wolff, A. C. et al. Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American Pathologists Guideline Update. J. Clin. Oncol. 41, 3867\u20133872 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1189_CR12","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1200\/JCO.2016.69.4836","volume":"35","author":"AN Bartley","year":"2017","unstructured":"Bartley, A. N. et al. HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. J. Clin. Oncol. 35, 446\u2013464 (2017).","journal-title":"J. Clin. Oncol."},{"key":"1189_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11864-023-01166-0","volume":"25","author":"MK Anastasio","year":"2024","unstructured":"Anastasio, M. K., Shuey, S. & Davidson, B. A. Antibody-drug conjugates in gynecologic cancers. Curr. Treat. Options Oncol. 25, 1\u201319 (2024).","journal-title":"Curr. Treat. Options Oncol."},{"key":"1189_CR14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.23.02005","volume":"42","author":"F Meric-Bernstam","year":"2024","unstructured":"Meric-Bernstam, F. et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 Phase II Trial. J. Clin. Oncol. 42, 47\u201358 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1189_CR15","doi-asserted-by":"publisher","first-page":"S1990","DOI":"10.1016\/S0167-8140(23)67126-9","volume":"182","author":"M Xu","year":"2023","unstructured":"Xu, M. et al. Early data of a phase II study of PRaG3.0 regimen for remedy of HER2-expressing advanced pan-cancer. Radiother. Oncol. 182, S1990 (2023).","journal-title":"Radiother. Oncol."},{"key":"1189_CR16","doi-asserted-by":"publisher","first-page":"e14614","DOI":"10.1200\/JCO.2023.41.16_suppl.e14614","volume":"41","author":"ML Xu","year":"2023","unstructured":"Xu, M. L. et al. A multicenter, phase II trial of RC48-ADC combined with radiotherapy, PD-1\/PD-L1 inhibitor, GM-CSF, and sequential IL-2 (PRaG3.0 regimen) for salvage therapy in patients with HER2-expressing advanced solid tumors. J. Clin. Oncol. 41, e14614 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1189_CR17","doi-asserted-by":"publisher","first-page":"e0257976","DOI":"10.1371\/journal.pone.0257976","volume":"16","author":"B Itkin","year":"2021","unstructured":"Itkin, B. et al. Prevalence of HER2 overexpression and amplification in cervical cancer: a systematic review and meta-analysis. PLoS ONE 16, e0257976 (2021).","journal-title":"PLoS ONE"},{"key":"1189_CR18","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.semcancer.2020.02.016","volume":"72","author":"C Marchi\u00f2","year":"2021","unstructured":"Marchi\u00f2, C. et al. Evolving concepts in HER2 evaluation in breast cancer: heterogeneity, HER2-low carcinomas and beyond. Semin. Cancer Biol. 72, 123\u2013135 (2021).","journal-title":"Semin. Cancer Biol."},{"key":"1189_CR19","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1038\/s41379-021-00738-5","volume":"34","author":"A Katayama","year":"2021","unstructured":"Katayama, A. et al. Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer. Mod. Pathol. 34, 1271\u20131281 (2021).","journal-title":"Mod. Pathol."},{"key":"1189_CR20","first-page":"6110","volume":"11","author":"FP Branco","year":"2019","unstructured":"Branco, F. P. et al. Loss of HER2 and disease prognosis after neoadjuvant treatment of HER2+ breast cancer. Am. J. Transl. Res. 11, 6110\u20136116 (2019).","journal-title":"Am. J. Transl. Res."},{"key":"1189_CR21","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1038\/s41379-020-0615-z","volume":"33","author":"R Chen","year":"2020","unstructured":"Chen, R., Qarmali, M., Siegal, G. P. & Wei, S. Receptor conversion in metastatic breast cancer: analysis of 390 cases from a single institution. Mod. Pathol. 33, 2499\u20132506 (2020).","journal-title":"Mod. Pathol."},{"key":"1189_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-021-00343-4","volume":"7","author":"F Miglietta","year":"2021","unstructured":"Miglietta, F. et al. Evolution of HER2-low expression from primary to recurrent breast cancer. NPJ Breast Cancer 7, 137 (2021).","journal-title":"NPJ Breast Cancer"}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-01189-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-01189-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-01189-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T05:19:16Z","timestamp":1767071956000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-01189-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1189"],"URL":"https:\/\/doi.org\/10.1038\/s41698-025-01189-w","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"assertion":[{"value":"30 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"410"}}